Journal
NATURE REVIEWS CLINICAL ONCOLOGY
Volume 15, Issue 1, Pages 11-+Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2017.156
Keywords
-
Categories
Funding
- Laura and John Arnold Foundation
Ask authors/readers for more resources
On 30th August 2017, tisagenlecleucel became the first chimeric antigen receptor (CAR)-T-cell therapy to be approved by the FDA. This approval has important implications for health-care systems because the use of this promising treatment presents considerable logistical, toxicological, and financial challenges. Moreover, the high price tag of US$475,000 is questionable, considering the major role of US taxpayers in covering the development, delivery, and supportive-care costs of this treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available